Effect of Carthamus tinctorius L. (Safflower) on National Institute of Health Stroke Scale Scores of Ischemic Stroke Patients: A Pilot Clinical Trial
-
Mahdi Yousefi
,
Payam Sasannezhad
,
Hassan Rakhshande
,
Hassan Doosti
,
Azadeh Saki
,
Zahra Baghestani Kouzegar
,
Hamideh Ahmadi
,
Elahe Delshad
Abstract
Experiencing complications within the first two weeks after stroke leads to a high risk of mortality and length of hospitalization. The present pilot study was intended to investigate the hypothesis that adult patients treated with safflower or not would present with fewer neurological complications following 15 days. In a randomized controlled trial, subjects diagnosed with ischemic cerebrovascular accident (CVA) based on focal neurological findings on brain imaging who met the inclusion criteria of our study were recruited from Ghaem Hospital, Mashhad, Iran, between 2016 and 2017. Thirty-six patients were included in the survey and randomly allocated into treatment (A) and control (B) groups. An oral syrup of safflower extract and nasal drop of safflower oil were additionally prescribed for group A. Group B only received a standard anti-ischemic regimen. The primary outcome measure was the National Institutes of Health Stroke Scale score (NIHSS) over 15 days. Safflower treatment led to a notably higher mean difference in the NIHSS score between the baseline score and 15-day post-treatment score in group A in comparison to group B (p < 0.001). However, adjustment for covariates (age, gender, and baseline measures) showed no significant reduction in neurological status between them (p = 0.340). There was a statistically significant difference in neurological symptom scores between the groups (p = 0.044). Based on this pilot study, adjuvant treatment with safflower in addition to the standard anti-ischemic regimen can be more effective than individual conventional drugs for treating ischemic CVA among adults.
Marini C, Russo T, Felzani G. Incidence of stroke in young adults: a review. Stroke Res Treat 2011;2011: 535672.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, et al. Heart disease and stroke statistics—2017 update: a report from the american heart association. Circulation 2017;135:e146-e603.
Venketasubramanian N, Yoon BW, Pandian J, Navarro JC. Stroke epidemiology in south, east, and south-east asia: a review. J Stroke 2017;19:286-294.
Krishnamurthi RV, Moran AE, Feigin VL, Barker-Collo S, Norrving B, et al. Stroke prevalence, mortality and disability-adjusted life years in adults aged 20-64 years in 1990-2013: data from the global burden of disease 2013 study. Neuroepidemiology 2015;45:190-202.
Guan T, Ma J, Li M, Xue T, Lan Z, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology 2017:89:53-61.
Swanepoel AC, Pretorius E. Prevention and follow-up in thromboembolic ischemic stroke: do we need to think out of the box? Thromb Res 2015;136:1067-1073.
Tavakoli Rezaee H, Kamrani N. The effect of ascorbic acid on infarction volume and neurological disorders following stroke of embolic model in rats. J Rafsanjan Univ Med Sci 2009;8:49-58.
Zargaran A, Zarshenas MM, Karimi A, Yarmohammadi H, Borhani-Haghighi A. Management of stroke as described by Ibn Sina (Avicenna) in the Canon of Medicine. Int J Cardiol Heart Vasc 2013;169:233-237.
Omidi R, Zali H, Rezaee TM, Modara F. Investigation of ischemic stroke mechanism by analyzing human brain proteome. J Ilam Uni Med Sci 2013;21:98-108.
Attari F, Karimzadeh F, Gorji A. Acute ischemic stroke: Pathophysiology and stem cell therapy. J Paramed 2013;7:46-51.
Giele JL, Witkamp TD, Mali WP, van der Graaf Y. Silent brain infarcts in patients with manifest vascular disease. Stroke 2004;35:742-746.
Xing C, Arai K, Lo EH, Hommel M. Pathophysiologic cascades in ischemic stroke. Int J Stroke 2012;7:378-385.
Pan J, Konstas A-A, Bateman B, Ortolano GA, Pile-Spellman J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology 2007; 49:93-102.
Rahnema M, Foroozandeh M, Ghasemloo E. The effect of hydroalcoholic extract of Satureja hortensis on outcomes of stroke in rats. Feyz 2016;19:511-519.
Juttler E, Kohrmann M, Schellinger PD. Therapy for early reperfusion after stroke. Nat Clin Pract Cardiovasc Med 2006;3:656-663.
Cheng NT, Kim AS. Intravenous Thrombolysis for acute ischemic stroke within 3 hours versus between 3 and 4.5 hours of symptom onset. Neurohospitalist 2015;5:101-109.
Fu Y, Wang Y, Zhang B. Systems pharmacology for traditional Chinese medicine with application to cardio-cerebrovascular diseases. J Tradit Chin Med Sci 2014;1:84-91.
Behravan E, Razavi BM, Hosseinzadeh H. Review of plants and their constituents in the therapy of cerebral ischemia. Phytother Res 2014;28:1265-1274.
Chen YF. Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci 2012;4:809-817.
Naderi G, Jaefari Dinani N, Nejabat N, Kelardasht M, Jaefarian Dehkordi A, et al. Fibrinolytic activity of the polyphenolic extract of Curcuma domestica Valet., Cinnamomum verum J. Presl, Heracleum persicum Desf. Ex Fischer, and Zataria multiflora Boiss. in in vitro. Iranian Journal of Medicinal and Aromatic Plants Research 2011;4:572-580.
Derex L, Paris C, Nighoghossian N. Combining intravenous thrombolysis and antithrombotic agents in stroke: an update. J Am Heart Assoc 2018;7:54-74.
Wafa HA, Wolfe CDA, Rudd A, Wang Y. Long-term trends in incidence and risk factors for ischaemic stroke subtypes: prospective population study of the south london stroke register. PLoS Med 2018;15:26-49.
Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs 2013;13:57-59.
Tummers JFMM, Schrijvers AJP, Visser-Meily JMA. Economic evidence on integrated care for stroke patients; a systematic review. Int J Integr Care 2012;12:1-15.
Pan W, Yang X, Zhou H. The development of integrative medicine. Integr Med Int 2016;3: 96-98.
Gaire BP. Herbal medicine in ischemic stroke: challenges and prospective. Chin J Integr Med 2018;24:243-246.
Zhang J, Onakpoya IJ, Posadzki P, Eddouks M. The safety of herbal medicine: from prejudice to evidence. Evid -Based Complement Altern Med 2015;2015:316706.
Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 2001;35:501-504.
Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 2012;21:404-428.
Kim H. Neuroprotective herbs for stroke therapy in traditional eastern medicine. Neurol Res 2005;27:287-301.
Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002;71:655-665.
Wang Q, Simonyi A, Li W, Sinnenesk BA, Miller RL, et al. Dietary grape supplement ameliorates cerebral ischemia-induced neuronal death in gerbils. Mol Nutr Food Res 2005;49:443-451.
Jiang J, Wang W, Sun YJ, Hu M, Li F, et al. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 2007;561:54-62.
Yao D, Wang Z, Miao L, Wang L. Effects of extracts and isolated compounds from safflower on some index of promoting blood circulation and regulating menstruation. J Ethnopharmacol 2016;191:264-272.
Zhou X, Tang L, Xu Y, Zhou G, Wang Z. Towards a better understanding of medicinal uses of Carthamus tinctorius L. in traditional Chinese medicine: a phytochemical and pharmacological review. J Ethnopharmacol 2014;151:27-43.
Delshad E, Yousefi M, Sasannezhad P, Rakhshandeh H, Ayati Z. Medical uses of carthamus tinctorius L. (Safflower): a comprehensive review from traditional medicine to modern medicine. Electron Physician 2018;10:6672-6681.
Tu Y, Xue Y, Guo D, Sun L, Guo M. Carthami flos: a review of its ethnopharmacology, pharmacology and clinical applications. Rev Bras Farmacogn 2015;25:553-566.
Ma L, Li D, Li K. Clinical effect study on ischemic stroke in acute period treated with red flower injection. J Zhejiang Chin Med Univ 2012;36:633-635.
Xiao X, Hu W. Clinical effect of HSYA injection on acute ischemic apoplexy. Med J West China 2011;33:932-936.
Xing Y, Tu Q, Xiao Q, Jiao Y. Clinical effect of safflower yellow injection on ischemic apoplexy. Chin Hosp Pharm J 2008;28:1493-1495.
Browne RH. On the use of a pilot sample for sample size determination. Stat Med 1995;14:1933-1940.
Imami A, Taleb A, Khalili H. PDR for Herbal Medicines. 1st ed. Andisheh-Avar. Tehran 2010.
Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
Zargari A. Mdical Herbs. Tehran University Press. Tehran 2012.
Fattahi M, Nobakht M, Mahmoudian M. The teratogenic effect of Golrang’s extract on development of CNS in mouse. Razi Journal of Medical Sciences 2000;7:138-143.
Mozafarian V. Recognition of Medicinal and Aromatic Herbs in Iran. Farhang-e-Moaser. Tehran 2012.
Zakaria al-Razi M. Al-Havi fi al-Teb. Dar al-Hayat al-Torath al-Arabi. Beirut 2001.
Aghili Khorasani MH. Makhzan Aladviyeh. Sabz-arang Press. Tehran 2012.
Yousefi M, Rakhshandeh H, Delshad E, Mahjoub F. Assessment of clot lytic effect of Carthamus tinctorius (Golrang). Avicenna J Phytomed 2015;5:78. 1/2p.
Ye S-Y, Gao W-Y. Hydroxysafflor yellow A protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats. Arch Pharm Res 2008;31:1010-1015.
Zhu H, Wang Z, Ma C, Tian J, Fu F, et al. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies. Planta Med 2003;69:429-433.
Luo J, Fang Z, Zhou L, Lai S. Effects of carthamus tinctorius injection on bcl-2, caspase-3 expression related to neurons apoptosis after local cerebral ischemia. Zhongguo Zhong Yao Za Zhi 2004;29:977-980.
Zhao Q, Du J-S, Han X-m, Xu F, Yang X, et al. Research of apotosis after acute cerebral ischemia reperfusion in rat brain and safflower protection mechanism. Chin J Lab Med 2004;8:006.
Yu-Ye X, Yang M, Sheng Y-C. Neuroprotective effect of hydroxysafflor yellow A on cerebral ischemia injuries in rats. Chinese Journal of Pharmaceuticals. 2005;36:1-18.
Wei X, Liu H, Sun X, Fu F, Zhang X, et al. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci Lett 2005;386:58-62.
Li H-X, Han S-Y, Wang X-W, Ma X, Zhang K, et al. Effect of the carthamins yellow from Carthamus tinctorius L. on hemorheological disorders of blood stasis in rats. Food Chem Toxicol 2009;47:1797-802.
Sun L, Yang L, Xu Y-W, Liang H, Han J, et al. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood–brain barrier disruption. Brain Res 2012;1473:227-235.
Chen L, Xiang Y, Kong L, Zhang X, Sun B, et al. Hydroxysafflor yellow A protects against cerebral ischemia–reperfusion injury by anti-apoptotic effect through PI3K/Akt/GSK3β pathway in rat. Neurochem Res 2013;38:2268-2275.
Wu S-H, Zheng C-P, Chen S-Y, Cai X-P, Shi Y-J, et al. Anti-thrombotic effect of carthamus tinctorius linn extracts in rats. Trop J Pharm Res 2014;13:1637-1642.
Namjoo A, Rafieian M, Azizi S, Talebi-Juneghani A. Histopathologic effects of carthamus tinctorius on the brain liver and kidney of the new born mice. J Shahrekord Univ Med Sci 2010; 11:38-45.
Fan S, Lin N, Shan G, Zuo P, Cui L. Safflower yellow for acute ischemic stroke: a systematic review of randomized controlled trials. Complement Ther Med 2014;22:354-361.
Fu P-K, Pan T-L, Yang C-Y, Jeng K-C, Tang N-Y, et al. Carthamus tinctorius L. ameliorates brain injury followed by cerebral ischemia-reperfusion in rats by antioxidative and anti-inflammatory mechanisms. Iranian jouenrnal of basic medical sciences. 2016;19:1368-1375.
Heber D. PDR for herbal medicines. Montvale. Thomson 2004.
| Files | ||
| Issue | Vol 7, No 2, 2022 | |
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/tim.v7i2.9922 | |
| Keywords | ||
| Traditional medicine Carthamus tinctorius Stroke Controlled randomized trial | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
